Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002
Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
Role of thrombin-activatable fibrinolysis inhibitor in lipopolysaccharide-induced acute lung injury Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 461s Year: 2005
Role of thrombin-activatable fibrinolysis inhibitor in bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Decreased levels of secretory leucoprotease inhibitor in the pseudomonas -infected cystic fibrosis lung are due to neutrophil elastase degradation Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018
A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012
Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation Source: Eur Respir J 2007; 30: 423-428 Year: 2007
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Increased intraalveolar level of soluble endothelial protein C receptor in patients with interstitial lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 319s Year: 2004
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition Source: Eur Respir J 2011; 37: 1083-1090 Year: 2011
Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Matrix metalloprotease-1 and tissue inhibitor of metalloprotease-1 levels in pleural effusions of different origins Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
Activated protein C protection in endotoxin-induced lung injury is mediated by lung matrix metalloproteinases activity Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections Year: 2007
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Correlation between tenascin C and tissue factor in patients with interstitial lung disease Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003
Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005